Loading…

Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database

Background Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mo...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2021-08, Vol.125 (3), p.458-464
Main Authors: Jensen, Kristian Hastoft, Vogelius, Ivan, Moser, Claus Ernst, Andersen, Elo, Eriksen, Jesper Grau, Johansen, Jørgen, Farhadi, Mohammad, Andersen, Maria, Overgaard, Jens, Friborg, Jeppe
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3
cites cdi_FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3
container_end_page 464
container_issue 3
container_start_page 458
container_title British journal of cancer
container_volume 125
creator Jensen, Kristian Hastoft
Vogelius, Ivan
Moser, Claus Ernst
Andersen, Elo
Eriksen, Jesper Grau
Johansen, Jørgen
Farhadi, Mohammad
Andersen, Maria
Overgaard, Jens
Friborg, Jeppe
description Background Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mortality of bloodstream infections (BSIs) after RT/CRT. Methods Patients with HNSCC of the pharynx, larynx and oral cavity treated with curative-intent RT/CRT in Denmark between 2010 and 2017 and subsequent BSI episodes occurring within 18 months of RT/CRT initiation were identified in national registries. Results We included 5674 patients and observed 238 BSIs. Increasing age, stage and performance status were significantly associated with an elevated BSI risk, while sex, smoking and high-grade mucositis were not. Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk. Staphylococcus aureus accounted for 34% of episodes occurring during the first 3 months. The 30-day post-BSI mortality rate was 26% (95% confidence interval: 19–32) and BSIs were involved in 10% of early non-cancer deaths. Conclusion The risk of BSI development is associated with several patient- and disease-related factors and BSIs contribute considerably to early non-cancer mortality. Empiric antibiotic treatment regimens should prioritise coverage for S. aureus when treating suspected systemic infection in this population.
doi_str_mv 10.1038/s41416-021-01430-w
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8329195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2557304608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3</originalsourceid><addsrcrecordid>eNp9Uc1u1DAQthCILoUX4IAscTaM4zhOOCDRhbZIFVzgbE1sp5uyawfbabVvxGPibdoCF072zHw_M_oIecnhDQfRvk01r3nDoOIMeC2A3TwiKy5FxXhbqcdkBQCKQVfBEXmW0lUpO2jVU3IkauAK2npFfp1sQ7ApR4c7OvrBmTwGn8qXbhxait5S78wPatAbF-mEeXQ-J4pDLqWZY2lcOzb6XNo0oh1D3riI0_4dRTqFad7iQZL1mJylKc92T4cYdrTA6Ef0Y9rQ83urLwer9WJ1FsM8UYsZD9Tn5MmA2-Re3L3H5Pvpp2_rc3bx9ezz-sMFM7KGzCy2Emoz8N66oe9ASV5xJ3qLalBCKiN4A4oLPvRSml5UOEhXy67hvFGN6MUxeb_oTnO_c9aUqyJu9RTHHca9Djjqfyd-3OjLcK1bUXW8k0Xg9Z1ADD9nl7K-CnP0ZWddSakE1A20BVUtKBNDStENDw4c9CFdvaSrS7r6Nl19U0iv_t7tgXIfZwGIBZDKyF-6-Mf7P7K_AcUVtHk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2557304608</pqid></control><display><type>article</type><title>Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database</title><source>Springer Nature</source><source>PubMed Central</source><creator>Jensen, Kristian Hastoft ; Vogelius, Ivan ; Moser, Claus Ernst ; Andersen, Elo ; Eriksen, Jesper Grau ; Johansen, Jørgen ; Farhadi, Mohammad ; Andersen, Maria ; Overgaard, Jens ; Friborg, Jeppe</creator><creatorcontrib>Jensen, Kristian Hastoft ; Vogelius, Ivan ; Moser, Claus Ernst ; Andersen, Elo ; Eriksen, Jesper Grau ; Johansen, Jørgen ; Farhadi, Mohammad ; Andersen, Maria ; Overgaard, Jens ; Friborg, Jeppe</creatorcontrib><description>Background Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mortality of bloodstream infections (BSIs) after RT/CRT. Methods Patients with HNSCC of the pharynx, larynx and oral cavity treated with curative-intent RT/CRT in Denmark between 2010 and 2017 and subsequent BSI episodes occurring within 18 months of RT/CRT initiation were identified in national registries. Results We included 5674 patients and observed 238 BSIs. Increasing age, stage and performance status were significantly associated with an elevated BSI risk, while sex, smoking and high-grade mucositis were not. Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk. Staphylococcus aureus accounted for 34% of episodes occurring during the first 3 months. The 30-day post-BSI mortality rate was 26% (95% confidence interval: 19–32) and BSIs were involved in 10% of early non-cancer deaths. Conclusion The risk of BSI development is associated with several patient- and disease-related factors and BSIs contribute considerably to early non-cancer mortality. Empiric antibiotic treatment regimens should prioritise coverage for S. aureus when treating suspected systemic infection in this population.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-021-01430-w</identifier><identifier>PMID: 34017084</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028/67/1536 ; 692/4028/67/2324 ; Aged ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Chemoradiotherapy ; Chemoradiotherapy - adverse effects ; Databases, Factual ; Denmark - epidemiology ; Disseminated infection ; Drug Resistance ; Epidemiology ; Female ; Head &amp; neck cancer ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - radiotherapy ; Head and Neck Neoplasms - virology ; Human papillomavirus ; Humans ; Larynx ; Male ; Middle Aged ; Molecular Medicine ; Mortality ; Mucositis ; Oncology ; Oral cavity ; Oropharyngeal cancer ; Papillomavirus Infections - epidemiology ; Patients ; Pharynx ; Population studies ; Population-based studies ; Prognosis ; Radiation therapy ; Radiotherapy - adverse effects ; Registries ; Risk Factors ; Sepsis - epidemiology ; Sepsis - microbiology ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck - drug therapy ; Squamous Cell Carcinoma of Head and Neck - radiotherapy ; Squamous Cell Carcinoma of Head and Neck - virology ; Staphylococcus aureus ; Staphylococcus aureus - classification ; Staphylococcus aureus - isolation &amp; purification ; Survival Analysis ; Throat cancer</subject><ispartof>British journal of cancer, 2021-08, Vol.125 (3), p.458-464</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Limited.</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3</citedby><cites>FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3</cites><orcidid>0000-0002-0814-8179</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329195/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329195/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34017084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jensen, Kristian Hastoft</creatorcontrib><creatorcontrib>Vogelius, Ivan</creatorcontrib><creatorcontrib>Moser, Claus Ernst</creatorcontrib><creatorcontrib>Andersen, Elo</creatorcontrib><creatorcontrib>Eriksen, Jesper Grau</creatorcontrib><creatorcontrib>Johansen, Jørgen</creatorcontrib><creatorcontrib>Farhadi, Mohammad</creatorcontrib><creatorcontrib>Andersen, Maria</creatorcontrib><creatorcontrib>Overgaard, Jens</creatorcontrib><creatorcontrib>Friborg, Jeppe</creatorcontrib><title>Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mortality of bloodstream infections (BSIs) after RT/CRT. Methods Patients with HNSCC of the pharynx, larynx and oral cavity treated with curative-intent RT/CRT in Denmark between 2010 and 2017 and subsequent BSI episodes occurring within 18 months of RT/CRT initiation were identified in national registries. Results We included 5674 patients and observed 238 BSIs. Increasing age, stage and performance status were significantly associated with an elevated BSI risk, while sex, smoking and high-grade mucositis were not. Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk. Staphylococcus aureus accounted for 34% of episodes occurring during the first 3 months. The 30-day post-BSI mortality rate was 26% (95% confidence interval: 19–32) and BSIs were involved in 10% of early non-cancer deaths. Conclusion The risk of BSI development is associated with several patient- and disease-related factors and BSIs contribute considerably to early non-cancer mortality. Empiric antibiotic treatment regimens should prioritise coverage for S. aureus when treating suspected systemic infection in this population.</description><subject>692/4028/67/1536</subject><subject>692/4028/67/2324</subject><subject>Aged</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Chemoradiotherapy</subject><subject>Chemoradiotherapy - adverse effects</subject><subject>Databases, Factual</subject><subject>Denmark - epidemiology</subject><subject>Disseminated infection</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Head &amp; neck cancer</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Head and Neck Neoplasms - virology</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Larynx</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Mortality</subject><subject>Mucositis</subject><subject>Oncology</subject><subject>Oral cavity</subject><subject>Oropharyngeal cancer</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Patients</subject><subject>Pharynx</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Radiotherapy - adverse effects</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Sepsis - epidemiology</subject><subject>Sepsis - microbiology</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck - drug therapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - radiotherapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - virology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - classification</subject><subject>Staphylococcus aureus - isolation &amp; purification</subject><subject>Survival Analysis</subject><subject>Throat cancer</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9Uc1u1DAQthCILoUX4IAscTaM4zhOOCDRhbZIFVzgbE1sp5uyawfbabVvxGPibdoCF072zHw_M_oIecnhDQfRvk01r3nDoOIMeC2A3TwiKy5FxXhbqcdkBQCKQVfBEXmW0lUpO2jVU3IkauAK2npFfp1sQ7ApR4c7OvrBmTwGn8qXbhxait5S78wPatAbF-mEeXQ-J4pDLqWZY2lcOzb6XNo0oh1D3riI0_4dRTqFad7iQZL1mJylKc92T4cYdrTA6Ef0Y9rQ83urLwer9WJ1FsM8UYsZD9Tn5MmA2-Re3L3H5Pvpp2_rc3bx9ezz-sMFM7KGzCy2Emoz8N66oe9ASV5xJ3qLalBCKiN4A4oLPvRSml5UOEhXy67hvFGN6MUxeb_oTnO_c9aUqyJu9RTHHca9Djjqfyd-3OjLcK1bUXW8k0Xg9Z1ADD9nl7K-CnP0ZWddSakE1A20BVUtKBNDStENDw4c9CFdvaSrS7r6Nl19U0iv_t7tgXIfZwGIBZDKyF-6-Mf7P7K_AcUVtHk</recordid><startdate>20210803</startdate><enddate>20210803</enddate><creator>Jensen, Kristian Hastoft</creator><creator>Vogelius, Ivan</creator><creator>Moser, Claus Ernst</creator><creator>Andersen, Elo</creator><creator>Eriksen, Jesper Grau</creator><creator>Johansen, Jørgen</creator><creator>Farhadi, Mohammad</creator><creator>Andersen, Maria</creator><creator>Overgaard, Jens</creator><creator>Friborg, Jeppe</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0814-8179</orcidid></search><sort><creationdate>20210803</creationdate><title>Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database</title><author>Jensen, Kristian Hastoft ; Vogelius, Ivan ; Moser, Claus Ernst ; Andersen, Elo ; Eriksen, Jesper Grau ; Johansen, Jørgen ; Farhadi, Mohammad ; Andersen, Maria ; Overgaard, Jens ; Friborg, Jeppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/4028/67/1536</topic><topic>692/4028/67/2324</topic><topic>Aged</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Chemoradiotherapy</topic><topic>Chemoradiotherapy - adverse effects</topic><topic>Databases, Factual</topic><topic>Denmark - epidemiology</topic><topic>Disseminated infection</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Head &amp; neck cancer</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Head and Neck Neoplasms - virology</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Larynx</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Mortality</topic><topic>Mucositis</topic><topic>Oncology</topic><topic>Oral cavity</topic><topic>Oropharyngeal cancer</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Patients</topic><topic>Pharynx</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Radiotherapy - adverse effects</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Sepsis - epidemiology</topic><topic>Sepsis - microbiology</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck - drug therapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - radiotherapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - virology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - classification</topic><topic>Staphylococcus aureus - isolation &amp; purification</topic><topic>Survival Analysis</topic><topic>Throat cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensen, Kristian Hastoft</creatorcontrib><creatorcontrib>Vogelius, Ivan</creatorcontrib><creatorcontrib>Moser, Claus Ernst</creatorcontrib><creatorcontrib>Andersen, Elo</creatorcontrib><creatorcontrib>Eriksen, Jesper Grau</creatorcontrib><creatorcontrib>Johansen, Jørgen</creatorcontrib><creatorcontrib>Farhadi, Mohammad</creatorcontrib><creatorcontrib>Andersen, Maria</creatorcontrib><creatorcontrib>Overgaard, Jens</creatorcontrib><creatorcontrib>Friborg, Jeppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensen, Kristian Hastoft</au><au>Vogelius, Ivan</au><au>Moser, Claus Ernst</au><au>Andersen, Elo</au><au>Eriksen, Jesper Grau</au><au>Johansen, Jørgen</au><au>Farhadi, Mohammad</au><au>Andersen, Maria</au><au>Overgaard, Jens</au><au>Friborg, Jeppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2021-08-03</date><risdate>2021</risdate><volume>125</volume><issue>3</issue><spage>458</spage><epage>464</epage><pages>458-464</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mortality of bloodstream infections (BSIs) after RT/CRT. Methods Patients with HNSCC of the pharynx, larynx and oral cavity treated with curative-intent RT/CRT in Denmark between 2010 and 2017 and subsequent BSI episodes occurring within 18 months of RT/CRT initiation were identified in national registries. Results We included 5674 patients and observed 238 BSIs. Increasing age, stage and performance status were significantly associated with an elevated BSI risk, while sex, smoking and high-grade mucositis were not. Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk. Staphylococcus aureus accounted for 34% of episodes occurring during the first 3 months. The 30-day post-BSI mortality rate was 26% (95% confidence interval: 19–32) and BSIs were involved in 10% of early non-cancer deaths. Conclusion The risk of BSI development is associated with several patient- and disease-related factors and BSIs contribute considerably to early non-cancer mortality. Empiric antibiotic treatment regimens should prioritise coverage for S. aureus when treating suspected systemic infection in this population.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34017084</pmid><doi>10.1038/s41416-021-01430-w</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0814-8179</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2021-08, Vol.125 (3), p.458-464
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8329195
source Springer Nature; PubMed Central
subjects 692/4028/67/1536
692/4028/67/2324
Aged
Biomedical and Life Sciences
Biomedicine
Cancer Research
Chemoradiotherapy
Chemoradiotherapy - adverse effects
Databases, Factual
Denmark - epidemiology
Disseminated infection
Drug Resistance
Epidemiology
Female
Head & neck cancer
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - radiotherapy
Head and Neck Neoplasms - virology
Human papillomavirus
Humans
Larynx
Male
Middle Aged
Molecular Medicine
Mortality
Mucositis
Oncology
Oral cavity
Oropharyngeal cancer
Papillomavirus Infections - epidemiology
Patients
Pharynx
Population studies
Population-based studies
Prognosis
Radiation therapy
Radiotherapy - adverse effects
Registries
Risk Factors
Sepsis - epidemiology
Sepsis - microbiology
Squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck - drug therapy
Squamous Cell Carcinoma of Head and Neck - radiotherapy
Squamous Cell Carcinoma of Head and Neck - virology
Staphylococcus aureus
Staphylococcus aureus - classification
Staphylococcus aureus - isolation & purification
Survival Analysis
Throat cancer
title Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A29%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bloodstream%20infections%20in%20head%20and%20neck%20cancer%20patients%20after%20curative-intent%20radiotherapy:%20a%20population-based%20study%20from%20the%20Danish%20Head%20and%20Neck%20Cancer%20Group%20database&rft.jtitle=British%20journal%20of%20cancer&rft.au=Jensen,%20Kristian%20Hastoft&rft.date=2021-08-03&rft.volume=125&rft.issue=3&rft.spage=458&rft.epage=464&rft.pages=458-464&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-021-01430-w&rft_dat=%3Cproquest_pubme%3E2557304608%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2557304608&rft_id=info:pmid/34017084&rfr_iscdi=true